江中药业表示，报告期内，面对行业结构性调整压力，公司持续加强品牌打造，围绕"大单品、强品 类"夯实核心业务根基；丰富营销策略，强化投入回报，优化费用结构，并深化精益制造，推进降本增 效，助力盈利水平提升。 北京商报讯（记者 丁宁）1月23日晚间，江中药业（600750）发布2025年业绩快报显示，2025年，公司 实现营业收入42.2亿元，同比减少4.87%；实现归属净利润9.06亿元，同比增长14.96%。 ...

中证智能财讯江中药业（600750）1月23日晚间披露2025年业绩快报，公司实现营业收入42.2亿元，同比下降4.87%；归母净利润9.06亿元，同比增长 14.96%；扣非净利润8.32亿元，同比增长11.1%；基本每股收益1.43元，加权平均净资产收益率为22.74%。以1月23日收盘价计算，江中药业目前市盈率 （TTM）约为16.43倍，市净率（LF）约3.91倍，市销率（TTM）约3.39倍。 以本次披露业绩快报数据计算，公司近年市盈率（TTM）图如下所示： 近年来市盈率变化情况 (倍) 1,200 10000 800 600 400 200 0 2020-12-37 -12-3- <1-06-30 * 2022-06-30 · 7-12-37 r }- 公司 -〇- 行业均值 100 ହି ୨୦ 80 70 60 50 40 32a44 30 2903 27d 20 140 43d 10 3.67 0 2020-12-37 |> 2027-12-37 1 2022-12-37 ' *-06-30 ' 1-06-30 3-12-37 . 2-06-30 ' 2n- ） 制图数据来自恒生聚源数据库 市 ...

北京商报讯（记者 王寅浩 宋雨盈）1月23日，江中药业发布2025年业绩快报，2025年，公司实现营业收 入42.2亿元，同比减少4.87%；实现归属于上市公司股东的净利润9.06亿元，同比增长14.96%；实现归 属于上市公司股东的扣除非经常性损益的净利润为8.32亿元，同比增长11.1%。 ...

Core Viewpoint - China Resources Pharmaceutical (华润医药) reported a revenue of RMB 4.22 billion for Jiangzhong Pharmaceutical in 2025, reflecting a year-on-year decline of 4.87%, while the net profit attributable to shareholders increased by 14.96% to RMB 906 million [1] Group 1: Financial Performance - Jiangzhong Pharmaceutical achieved a revenue of RMB 4.22 billion in 2025, down 4.87% compared to the previous year [1] - The net profit attributable to shareholders reached RMB 906 million, marking a year-on-year increase of 14.96% [1] Group 2: Strategic Initiatives - The company is focusing on strengthening brand development amidst structural adjustments in the industry [1] - Jiangzhong Pharmaceutical is enhancing its marketing strategies, optimizing cost structures, and deepening lean manufacturing practices to improve profitability [1]

Core Viewpoint - Jiangzhong Pharmaceutical reported its preliminary unaudited financial data for the year ending December 31, 2025, indicating a focus on brand building and core business consolidation amid structural industry adjustments [1] Financial Performance - For the year 2025, Jiangzhong Pharmaceutical achieved a revenue of RMB 4.22 billion, representing a year-on-year decline of 4.87% [1] - The net profit attributable to shareholders of the listed company was RMB 906 million, showing a year-on-year increase of 14.96% [1] Strategic Initiatives - The company is enhancing its marketing strategies, optimizing cost structures, and deepening lean manufacturing practices to improve profitability [1] - Jiangzhong Pharmaceutical is focusing on "big single products and strong categories" to solidify its core business foundation [1]

证券之星消息，1月23日中药板块较上一交易日上涨0.28%，*ST长药领涨。当日上证指数报收于 4136.16，上涨0.33%。深证成指报收于14439.66，上涨0.79%。中药板块个股涨跌见下表： 从资金流向上来看，当日中药板块主力资金净流出5.1亿元，游资资金净流出5225.91万元，散户资金净流 入5.62亿元。中药板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入(元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 000538 | 云南白药 | 2925.96万 | 3.91% | 124.39万 | 0.17% | -3050.36万 | -4.07% | | 002390 | 信邦制药 | 1707.83万 | 9.03% | -877.49万 | -4.64% | -830.34万 | -4.39% | | 600750 江中药业 | | 1112.58万 | 4.76% | 719.17万 | 3.08% | -- 1831. ...

证券代码：600750 证券简称：江中药业 公告编号：2026-003 本公告所载华润江中药业股份有限公司（以下简称"公司"）2025年度主要 财务数据为初步核算数据，未经会计师事务所审计，具体数据以公司2025年度的 定期报告中披露的数据为准，提请投资者注意投资风险。 一、2025年度主要财务数据和指标（未经审计） 单位：万元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度（％） | | --- | --- | --- | --- | | 营业总收入 | 421,950 | 443,545 | -4.87% | | 营业利润 | 119,851 | 102,830 | 16.55% | | 利润总额 | 121,230 | 102,561 | 18.20% | | 归属于上市公司股东的净利润 | 90,612 | 78,819 | 14.96% | | 归属于上市公司股东的扣除非 经常性损益的净利润 | 83,235 | 74,918 | 11.10% | | 基本每股收益（元） | 1.43 | 1.25 | 14.40% | | 加权平均净资产收益率 | 22.74% | 19.58% | 增加 ...

格隆汇1月23日丨江中药业(600750.SH)公布2025年年度业绩快报，报告期内，面对行业结构性调整压 力，公司持续加强品牌打造，围绕"大单品、强品类"夯实核心业务根基；丰富营销策略，强化投入回 报，优化费用结构，并深化精益制造，推进降本增效，助力盈利水平提升。2025年，公司实现营业收入 42.20亿元，同比减少4.87%；实现归属于上市公司股东的净利润9.06亿元，同比增长14.96%。 ...

人民财讯1月23日电，江中药业(600750)1月23日发布业绩快报，2025年公司实现营业总收入42.2亿元， 同比下滑4.87%；归属于上市公司股东的净利润9.06亿元，同比增长14.96%。 转自：证券时报 ...

Core Viewpoint - The article highlights the shift in health and wellness practices among younger generations, moving from traditional methods to modern products like probiotics and nutritional gummies, with Huaren Jiangzhong, a time-honored brand, adapting to this trend [1]. Group 1: Company Overview - Huaren Jiangzhong, a well-established brand with over 50 years of history, is known for its digestive health products [1]. - The company is evolving from traditional products like digestive tablets to modern offerings such as nutritional gummies, reflecting a new development phase [1]. Group 2: Industry Trends - There is a growing trend of "light health" among younger consumers, who prefer convenient and modern health products over traditional remedies [1]. - The article emphasizes that true heritage involves adapting traditional wisdom to contemporary consumer lifestyles, contributing to a healthier society [1].